Chondrial Therapeutics

Chondrial Therapeutics

Steven Plump founded Chondrial Therapeutics in 2014, locating the firm in the Philadelphia biotech corridor and focusing exclusively on rare mitochondrial disorders. Friedreich's ataxia, a progressive neurodegenerative condition affecting roughly 1 in 50,000 people, became the company's primary target. Chondrial advanced its lead compound, CTI-1601 — a fusion protein delivering human frataxin — from preclinical proof-of-concept into late-stage animal studies and secured regulatory clearance to begin Phase 1 trials in humans. The firm's strategy centered on one pathway: compile a mitochondrial-disease platform with a single lead asset, run early development internally, then transition the program into a vehicle with broader public-market access. In May 2020, Chondrial executed a reverse-merger with publicly traded Zafgen, Inc., forming Larimar Therapeutics and bringing CTI-1601 under ticker LRMR on Nasdaq (per the firms' official communications, 2020). The merged entity continued Phase 1 dose-escalation trials for adults with Friedreich's ataxia, later expanding into an open-label extension study and a separate adolescent trial, all with U.S. FDA Fast Track designation. Chondrial's footprint remained concentrated in Philadelphia post-merger, with the legacy entity retaining an equity stake in Larimar and its founder, Steven Plump, serving as chairman of the combined company. The firm's total team size was not publicly disclosed, but the core science drew on relationships with Children's Hospital of Philadelphia and the University of Pennsylvania's mitochondrial-research community. May 2020 remains the defining operational marker: the reverse merger with Zafgen closed, transforming a private biotechnology firm into the controlling interest behind a Nasdaq-listed therapeutics company. Chondrial's structural distinction lies in its full-company exit into a public shell — a tactic more common in the cash-biotech SPAC era but rare for a single-asset rare-disease firm. Rather than pursuing a traditional venture-backed multi-round raise toward an IPO, the firm merged its entire pipeline into an existing public platform, achieving liquidity and clinical funding in one transaction while preserving the founding team's governance influence through the board chair and legacy equity position.